MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations

By Y. Ladeiro, G. Couchy, C. Balabaud, P. Bioulac-Sage, L. Pelletier, S. Rebouissou, J. Zucman‐Rossi. Hepatology, 2008

711 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties (2009, neutral): “An altered miRNA expression was observed in a large variety of neoplasms (Lu et al., 2005), including HCC (Murakami et al., 2006; Braconi and Patel, 2008; Budhu et al., 2008; Ladeiro et al., 2008; Li et al., 2008; Wong et al., 2008).”
Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. (2011, background): “…miRNAs in HCC but none of them was based on deep sequencing (Gramantieri et al., 2007, 2008, 2009; Braconi and Patel, 2008; Ji et al., 2009a, 2009b; Ladeiro et al., 2008; Varnholt et al., 2008; Wang et al., 2008, 2009a; Wong et al., 2008; Murakami et al., 2006; Kutay et al., 2006; Budhu et al.,…”
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma (2009, background): “Hsa-miR-96 was also found upregulated in primary cells from chronic myeloid leukemia(38) and in hepatocellular tumors.(39) Moreover, we found hsa-miR-96 to be associated with Gleason score and biochemical relapse.”